Shopping Cart 0
Cart Subtotal
AED 0

EyePoint Pharmaceuticals Inc (PSDV) - Product Pipeline Analysis, 2019 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 2753

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 8258

Details

Summary

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint's iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company EyePoint Pharmaceuticals Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

EyePoint Pharmaceuticals Inc Company Overview

EyePoint Pharmaceuticals Inc Company Snapshot

EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview

EyePoint Pharmaceuticals Inc-Pipeline Analysis Overview

EyePoint Pharmaceuticals Inc-Key Facts

EyePoint Pharmaceuticals Inc-Major Products and Services

EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage

EyePoint Pharmaceuticals Inc Pipeline Products Overview

Durasert-Front Of Eye Disease

Durasert-Front Of Eye Disease Product Overview

Durasert-Knee Osteoarthritis

Durasert-Knee Osteoarthritis Product Overview

Durasert Latanoprost Implant

Durasert Latanoprost Implant Product Overview

DURASERT With TKI-Wet AMD

DURASERT With TKI-Wet AMD Product Overview

Tethadur System

Tethadur System Product Overview

YUTIQ-Shorter Duration

YUTIQ-Shorter Duration Product Overview

EyePoint Pharmaceuticals Inc-Key Competitors

EyePoint Pharmaceuticals Inc-Key Employees

EyePoint Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

EyePoint Pharmaceuticals Inc, Recent Developments

Aug 07, 2019: EyePoint Pharmaceuticals reports second quarter 2019 financial results and highlights recent company progress

Jul 15, 2019: EyePoint Pharmaceuticals appoints Wendy DiCicco, CPA, to board of directors

Jun 10, 2019: EyePoint Pharmaceuticals strengthens executive leadership team with key hires

May 01, 2019: EyePoint Pharmaceuticals presents positive YUTIQ 36-month follow-up phase 3 data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Apr 16, 2019: EyePoint Pharmaceuticals to present at upcoming medical Conferences

Mar 14, 2019: Eyepoint Pharmaceuticals reports fiscal period ended december 31, 2018 financial results and highlights recent clinical and operational developments

Feb 13, 2019: EyePoint Pharmaceuticals secures up to USD 60 million debt facility

Feb 04, 2019: EyePoint Pharmaceuticals announces U.S. commercial launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Jan 28, 2019: EyePoint Pharmaceuticals names David Guyer, M.D., to Board of Directors

Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type

EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage


List Of Table

List of Tables

EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview

EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type

EyePoint Pharmaceuticals Inc Pipeline Products by Indication

EyePoint Pharmaceuticals Inc, Key Facts

EyePoint Pharmaceuticals Inc, Major Products and Services

EyePoint Pharmaceuticals Inc Number of Pipeline Products by Development Stage

EyePoint Pharmaceuticals Inc Pipeline Products Summary by Development Stage

Durasert-Front Of Eye Disease-Product Status

Durasert-Front Of Eye Disease-Product Description

Durasert-Knee Osteoarthritis-Product Status

Durasert-Knee Osteoarthritis-Product Description

Durasert Latanoprost Implant-Product Status

Durasert Latanoprost Implant-Product Description

DURASERT With TKI-Wet AMD-Product Status

DURASERT With TKI-Wet AMD-Product Description

Tethadur System-Product Status

Tethadur System-Product Description

YUTIQ-Shorter Duration-Product Status

YUTIQ-Shorter Duration-Product Description

EyePoint Pharmaceuticals Inc, Key Employees

EyePoint Pharmaceuticals Inc, Subsidiaries

Glossary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

EyePoint Pharmaceuticals Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Radius Health Inc

Eli Lilly and Co

Akers Biosciences Inc

Company Profile

Company Profile Title

Summary

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint's iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company EyePoint Pharmaceuticals Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

EyePoint Pharmaceuticals Inc Company Overview

EyePoint Pharmaceuticals Inc Company Snapshot

EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview

EyePoint Pharmaceuticals Inc-Pipeline Analysis Overview

EyePoint Pharmaceuticals Inc-Key Facts

EyePoint Pharmaceuticals Inc-Major Products and Services

EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage

EyePoint Pharmaceuticals Inc Pipeline Products Overview

Durasert-Front Of Eye Disease

Durasert-Front Of Eye Disease Product Overview

Durasert-Knee Osteoarthritis

Durasert-Knee Osteoarthritis Product Overview

Durasert Latanoprost Implant

Durasert Latanoprost Implant Product Overview

DURASERT With TKI-Wet AMD

DURASERT With TKI-Wet AMD Product Overview

Tethadur System

Tethadur System Product Overview

YUTIQ-Shorter Duration

YUTIQ-Shorter Duration Product Overview

EyePoint Pharmaceuticals Inc-Key Competitors

EyePoint Pharmaceuticals Inc-Key Employees

EyePoint Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

EyePoint Pharmaceuticals Inc, Recent Developments

Aug 07, 2019: EyePoint Pharmaceuticals reports second quarter 2019 financial results and highlights recent company progress

Jul 15, 2019: EyePoint Pharmaceuticals appoints Wendy DiCicco, CPA, to board of directors

Jun 10, 2019: EyePoint Pharmaceuticals strengthens executive leadership team with key hires

May 01, 2019: EyePoint Pharmaceuticals presents positive YUTIQ 36-month follow-up phase 3 data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Apr 16, 2019: EyePoint Pharmaceuticals to present at upcoming medical Conferences

Mar 14, 2019: Eyepoint Pharmaceuticals reports fiscal period ended december 31, 2018 financial results and highlights recent clinical and operational developments

Feb 13, 2019: EyePoint Pharmaceuticals secures up to USD 60 million debt facility

Feb 04, 2019: EyePoint Pharmaceuticals announces U.S. commercial launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Jan 28, 2019: EyePoint Pharmaceuticals names David Guyer, M.D., to Board of Directors

Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type

EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage


List Of Table

List of Tables

EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview

EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type

EyePoint Pharmaceuticals Inc Pipeline Products by Indication

EyePoint Pharmaceuticals Inc, Key Facts

EyePoint Pharmaceuticals Inc, Major Products and Services

EyePoint Pharmaceuticals Inc Number of Pipeline Products by Development Stage

EyePoint Pharmaceuticals Inc Pipeline Products Summary by Development Stage

Durasert-Front Of Eye Disease-Product Status

Durasert-Front Of Eye Disease-Product Description

Durasert-Knee Osteoarthritis-Product Status

Durasert-Knee Osteoarthritis-Product Description

Durasert Latanoprost Implant-Product Status

Durasert Latanoprost Implant-Product Description

DURASERT With TKI-Wet AMD-Product Status

DURASERT With TKI-Wet AMD-Product Description

Tethadur System-Product Status

Tethadur System-Product Description

YUTIQ-Shorter Duration-Product Status

YUTIQ-Shorter Duration-Product Description

EyePoint Pharmaceuticals Inc, Key Employees

EyePoint Pharmaceuticals Inc, Subsidiaries

Glossary

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

EyePoint Pharmaceuticals Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Radius Health Inc

Eli Lilly and Co

Akers Biosciences Inc